Ensign Peak Advisors
FLNA

Ensign Peak Advisors’s Filana Therapeutics FLNA Stock Holding History

Ensign Peak Advisors’s Portfolio FLNA Stock Details FLNA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-36,496
Closed -$86.1K – 1721
2024
Q4 		$86.1K Buy
36,496
+20,100
+123% +$353K ﹤0.01% 1705
2024
Q3 		$483K Hold
16,396
– – ﹤0.01% 1614
2024
Q2 		$202K Buy
16,396
+1,850
+13% +$39K ﹤0.01% 1695
2024
Q1 		$295K Sell
14,546
-734
-5% -$16.9K ﹤0.01% 1693
2023
Q4 		$344K Hold
15,280
– – ﹤0.01% 1701
2023
Q3 		$254K Hold
15,280
– – ﹤0.01% 1712
2023
Q2 		$375K Hold
15,280
– – ﹤0.01% 1690
2023
Q1 		$369K Buy
15,280
+2,450
+19% +$67.9K ﹤0.01% 1689
2022
Q4 		$379K Buy
12,830
+2,600
+25% +$93.4K ﹤0.01% 1685
2022
Q3 		$428K Sell
10,230
-1,020
-9% -$27.5K ﹤0.01% 1540
2022
Q2 		$316K Hold
11,250
– – ﹤0.01% 1661
2022
Q1 		$418K Hold
11,250
– – ﹤0.01% 1629
2021
Q4 		$492K Buy
+11,250
New +$590K ﹤0.01% 1637

Other funds holding FLNA

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
N
Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Two Sigma Advisers
Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Ensign Peak Advisors's FLNA Position: Q1 2025 in Review

Ensign Peak Advisors sold out of Filana Therapeutics (FLNA) in Q1 2025, closing a stake of 36,496 shares — an estimated $86.1K sold.

Ensign Peak Advisors first reported a position in FLNA in Q4 2021 and held it in 13 quarters. The position peaked at $492K in Q4 2021. 117 funds tracked by Wall St. Rank hold FLNA as of Q1 2025.

  • Ensign Peak Advisors reported no remaining Filana Therapeutics position as of Q1 2025 after selling out during the quarter.
  • Ensign Peak Advisors sold 36,496 Filana Therapeutics shares in Q1 2025, an estimated $86.1K.
  • Ensign Peak Advisors first reported a position in Filana Therapeutics in Q4 2021 and held it in 13 quarters.
  • Ensign Peak Advisors's Filana Therapeutics position peaked at $492K in Q4 2021.
  • 117 funds tracked by Wall St. Rank held Filana Therapeutics as of Q1 2025.

Based on Ensign Peak Advisors's 13F filing for Q1 2025, filed 14 May 2025.